These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. Langlois MR; Chapman MJ; Cobbaert C; Mora S; Remaley AT; Ros E; Watts GF; Borén J; Baum H; Bruckert E; Catapano A; Descamps OS; von Eckardstein A; Kamstrup PR; Kolovou G; Kronenberg F; Langsted A; Pulkki K; Rifai N; Sypniewska G; Wiklund O; Nordestgaard BG; Clin Chem; 2018 Jul; 64(7):1006-1033. PubMed ID: 29760220 [TBL] [Abstract][Full Text] [Related]
4. Which Lipids Should Be Analyzed for Diagnostic Workup and Follow-up of Patients with Hyperlipidemias? Langlois MR; Nordestgaard BG Curr Cardiol Rep; 2018 Aug; 20(10):88. PubMed ID: 30120626 [TBL] [Abstract][Full Text] [Related]
6. Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group. Wilson PWF; Jacobson TA; Martin SS; Jackson EJ; Le NA; Davidson MH; Vesper HW; Frikke-Schmidt R; Ballantyne CM; Remaley AT J Clin Lipidol; 2021; 15(5):629-648. PubMed ID: 34802986 [TBL] [Abstract][Full Text] [Related]
8. Low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol and apolipoprotein B: relationships among the different measurements. Franzini C; Valente C; Luraschi P Scand J Clin Lab Invest; 2004; 64(8):703-7. PubMed ID: 15719888 [TBL] [Abstract][Full Text] [Related]
9. Clinical impact of direct HDLc and LDLc method bias in hypertriglyceridemia. A simulation study of the EAS-EFLM Collaborative Project Group. Langlois MR; Descamps OS; van der Laarse A; Weykamp C; Baum H; Pulkki K; von Eckardstein A; De Bacquer D; Borén J; Wiklund O; Laitinen P; Oosterhuis WP; Cobbaert C; Atherosclerosis; 2014 Mar; 233(1):83-90. PubMed ID: 24529127 [TBL] [Abstract][Full Text] [Related]
10. Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Charlton-Menys V; Betteridge DJ; Colhoun H; Fuller J; France M; Hitman GA; Livingstone SJ; Neil HA; Newman CB; Szarek M; DeMicco DA; Durrington PN Clin Chem; 2009 Mar; 55(3):473-80. PubMed ID: 19147732 [TBL] [Abstract][Full Text] [Related]
11. National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. Jacobson TA; Ito MK; Maki KC; Orringer CE; Bays HE; Jones PH; McKenney JM; Grundy SM; Gill EA; Wild RA; Wilson DP; Brown WV J Clin Lipidol; 2015; 9(2):129-69. PubMed ID: 25911072 [TBL] [Abstract][Full Text] [Related]
12. Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment. Carr SS; Hooper AJ; Sullivan DR; Burnett JR Pathology; 2019 Feb; 51(2):148-154. PubMed ID: 30595507 [TBL] [Abstract][Full Text] [Related]
13. Relation of cholesterol and lipoprotein parameters with carotid artery plaque characteristics: the Atherosclerosis Risk in Communities (ARIC) carotid MRI study. Virani SS; Catellier DJ; Pompeii LA; Nambi V; Hoogeveen RC; Wasserman BA; Coresh J; Mosley TH; Otvos JD; Sharrett AR; Boerwinkle E; Ballantyne CM Atherosclerosis; 2011 Dec; 219(2):596-602. PubMed ID: 21868017 [TBL] [Abstract][Full Text] [Related]
14. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels. Querton L; Buysschaert M; Hermans MP J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779 [TBL] [Abstract][Full Text] [Related]
15. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. Cziraky MJ; Watson KE; Talbert RL J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279 [TBL] [Abstract][Full Text] [Related]
16. Residual Atherosclerotic Cardiovascular Disease Risk: Focus on Non-High-Density Lipoprotein Cholesterol. Luo Y; Peng D J Cardiovasc Pharmacol Ther; 2023; 28():10742484231189597. PubMed ID: 37641208 [TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein B and non-high-density lipoprotein cholesterol reveal a high atherogenicity in individuals with type 2 diabetes and controlled low-density lipoprotein-cholesterol. Fonseca L; Paredes S; Ramos H; Oliveira JC; Palma I Lipids Health Dis; 2020 Jun; 19(1):127. PubMed ID: 32505210 [TBL] [Abstract][Full Text] [Related]
18. Non-HDL Cholesterol or apoB: Which to Prefer as a Target for the Prevention of Atherosclerotic Cardiovascular Disease? Langlois MR; Sniderman AD Curr Cardiol Rep; 2020 Jun; 22(8):67. PubMed ID: 32562186 [TBL] [Abstract][Full Text] [Related]
19. The extended lipid panel assay: a clinically-deployed high-throughput nuclear magnetic resonance method for the simultaneous measurement of lipids and Apolipoprotein B. Garcia E; Bennett DW; Connelly MA; Jeyarajah EJ; Warf FC; Shalaurova I; Matyus SP; Wolak-Dinsmore J; Oskardmay DN; Young RM; Sampson M; Remaley AT; Otvos JD Lipids Health Dis; 2020 Dec; 19(1):247. PubMed ID: 33261644 [TBL] [Abstract][Full Text] [Related]
20. [Consensus for pharmacologic treatment of atherogenic dyslipidemia with statin-fenofibrate combined therapy]. Panel Europeo de Expertos. Versión Española del Grupo de trabajo sobre Dislipemia Aterogénica Clin Investig Arterioscler; 2016; 28(2):87-93. PubMed ID: 26811267 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]